Table 3.

ROCO target coverage and rind maximum dose for three different cases: in the first row, no rinds are included in the optimization; in the second row, rind constraints are included in both the sampling and hard constraints; and in the third row, rind constraints are present in the hard constraint optimization step only. Patients 5, 7, 8, and 10 had unacceptable hot spots outside the PTV when rind structures were not included in the ROCO constraints. Rind constraints reduced these doses to acceptable levels (110% of PTV max dose), and the optimizer had sufficient freedom to do this even without the presence of rinds during sampling.

Patient	1	2	3	4	5	6	7	8	9	10	11	12
Rinds:	No rinds present.
PTV D95	100.6	100.2	100.9	100.4	95.4	101.0	91.7	99.2	100.6	99.3	100.6	99.0
Rind Dmax	109.6	107.4	106.1	106.2	119.9	104.5	115.5	110.7	108.5	114.3	107.5	109.9
Rinds:	Rinds present in both sampling and constrained optimization.
PTV D95	100.6	100.2	100.9	99.6	95.1	101.0	91.6	99.2	100.6	98.9	100.6	99.0
Rind Dmax	109.6	107.4	106.1	105.6	107.0	104.5	110.0	110.0	108.5	110.0	107.5	109.9
Rinds:	Rinds in constrained optimization only.
PTV D95	100.1	100.1	100.7	100.4	98.1	101.0	93.2	98.9	100.5	98.0	100.5	98.7
Rind Dmax	109.0	108.4	105.7	106.2	110.0	104.5	106.8	106.2	106.6	110.0	106.1	107.0